Piper Sandler initiated coverage on shares of Axcella Health (NASDAQ:AXLA) in a report published on Thursday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $25.00 target price on the stock.
A number of other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Axcella Health from a buy rating to a hold rating in a research report on Monday, July 20th. ValuEngine raised shares of Axcella Health from a buy rating to a strong-buy rating in a report on Thursday, May 14th. Wedbush began coverage on shares of Axcella Health in a research note on Wednesday, May 27th. They issued an outperform rating and a $28.00 target price on the stock. SVB Leerink decreased their price target on Axcella Health from $21.00 to $20.00 and set an outperform rating for the company in a research note on Monday, May 18th. Finally, BTIG Research lowered their price objective on Axcella Health from $28.00 to $16.00 and set a buy rating for the company in a report on Thursday, July 9th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $18.40.
NASDAQ:AXLA opened at $4.49 on Thursday. The firm has a 50-day moving average of $5.03 and a two-hundred day moving average of $4.59. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.91 and a quick ratio of 10.91. Axcella Health has a 1-year low of $2.25 and a 1-year high of $8.81.
In related news, major shareholder Ventures Fund Iv L.P Flagship acquired 3,800,000 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was purchased at an average cost of $4.20 per share, for a total transaction of $15,960,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David R. Epstein bought 50,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was bought at an average cost of $4.20 per share, for a total transaction of $210,000.00. Insiders own 10.40% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in AXLA. State Street Corp increased its holdings in shares of Axcella Health by 102.2% in the 1st quarter. State Street Corp now owns 115,765 shares of the company’s stock worth $396,000 after acquiring an additional 58,506 shares during the period. BlackRock Inc. grew its position in Axcella Health by 14.5% in the 1st quarter. BlackRock Inc. now owns 341,479 shares of the company’s stock worth $1,168,000 after purchasing an additional 43,339 shares during the last quarter. Geode Capital Management LLC acquired a new stake in shares of Axcella Health in the fourth quarter valued at approximately $155,000. Bank of New York Mellon Corp acquired a new stake in shares of Axcella Health in the fourth quarter valued at approximately $80,000. Finally, UBS Group AG raised its holdings in shares of Axcella Health by 1,168.2% during the fourth quarter. UBS Group AG now owns 19,073 shares of the company’s stock valued at $76,000 after buying an additional 17,569 shares during the last quarter. 43.13% of the stock is owned by institutional investors.
Axcella Health Company Profile
There is no company description available for Axcella Health Inc
Read More: Book Value Per Share in Stock Trading
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.